Nanocarriers for brain specific delivery of anti-retro viral drugs: challenges and achievements

References

• Trujillo JR, Jaramillo-Rangel G, Ortega-Martinez M, et al. International NeuroAIDS: prospects of HIV-1 associated neurological complications. Cell Res. 2005;15:962–969.
   PubMed Web of Science ®Google Scholar
• Maartens G, Celum C, Lewin SR. HIV infection: epidemiology, pathogenesis, treatment, and prevention. Lancet. 2014;384:258–271.
   PubMed Web of Science ®Google Scholar
• Koppensteiner H, Brack-Werner R, Schindler M. Macrophages and their relevance in human immunodeficiency virus type I infection. Retrovirology. 2012;9:82.
   PubMed Web of Science ®Google Scholar
• Hazleton JE, Berman JW, Eugenin EA. Novel mechanisms of central nervous system damage in HIV infection. HIV/AIDS – Res Palliat Care. 2010;2:39–49.
   Google Scholar
• Gras G, Kaul M. Molecular mechanisms of neuroinvasion by monocytes-macrophages in HIV-1 infection. Retrovirology. 2010;7:30
   PubMed Web of Science ®Google Scholar
• Banks WA, Freed EO, Wolf KM, et al. Transport of human immunodeficiency virus type 1 pseudoviruses across the blood-brain barrier: role of envelope proteins and adsorptive endocytosis. J Virol. 2001;75:4681–4691.
   PubMed Web of Science ®Google Scholar
• Banks WA, Kumar VB, Franko MW, et al. Evidence that the species barrier of human immunodeficiency virus-1 does not extend to uptake by the blood-brain barrier: comparison of mouse and human brain microvessels. Life Sci. 2005;77:2361–2368.
   PubMed Web of Science ®Google Scholar
• Minagar A, Commins D, Alexander JS, et al. NeuroAIDS: characteristics and diagnosis of the neurological complications of AIDS. Mol Diagn Ther. 2008;12:25–43.
   PubMed Web of Science ®Google Scholar
• McArthur JC, Brew BJ, Nath A. Neurological complications of HIV infection. Lancet Neurol. 2005;4:543–555.
   PubMed Web of Science ®Google Scholar
• Saxena SK, Tiwari S, Nair MPN. NeuroAIDS: mechanisms, causes, prevalence, diagnostics and social issues. In: Saxena SK, editor. Current perspectives in HIV infection. InTech; 2013. p. 109–124.
   Google Scholar
• McArthur JC. HIV dementia: an evolving disease. J Neuroimmunol. 2004;157:3–10.
   PubMed Web of Science ®Google Scholar
• Levy JA. Pathogenesis of human immunodeficiency virus infection. Microbiol Rev. 1993;57:183–289.
   PubMedGoogle Scholar
• Power C, Boissé L, Rourke S, et al. NeuroAIDS: an evolving epidemic. Can J Neurol Sci. 2009;36:285–295.
   PubMed Web of Science ®Google Scholar
• Atluri VSR, Hidalgo M, Samikkannu T, et al. Effect of human immunodeficiency virus on blood-brain barrier integrity and function: an update. Front Cell Neurosci. 2015;9:212.
   PubMed Web of Science ®Google Scholar
• Nair M, Jayant RD, Kaushik A, et al. Getting into the brain: potential of nanotechnology in the management of NeuroAIDS. Adv Drug Deliv Rev. 2016;103:202–217.
   PubMed Web of Science ®Google Scholar
• Zayyad Z, Spudich S. Neuropathogenesis of HIV: from initial neuroinvasion to HIV-associated neurocognitive disorder (HAND). Curr HIV/AIDS Rep. 2015;12:16–24.
   PubMed Web of Science ®Google Scholar
• Nath A. Human immunodeficiency virus (HIV) proteins in neuropathogenesis of HIV dementia. J Infect Dis. 2002;186 Suppl:S193–S198.
   Web of Science ®Google Scholar
• Banks WA, Ercal N, Price TO. The blood-brain barrier in neuroAIDS. Curr HIV Res. 2006;4:259–266.
   PubMed Web of Science ®Google Scholar
• González-Scarano F, Martín-García J. The neuropathogenesis of AIDS. Nat Rev Immunol. 2005;5:69–81.
   PubMed Web of Science ®Google Scholar
• Ellis R, Langford D, Masliah E. HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat Rev Neurosci. 2007;8:33–44.
   PubMed Web of Science ®Google Scholar
• Valcour V, Sithinamsuwan P, Letendre S, et al. Pathogenesis of HIV in the central nervous system. Curr HIV/AIDS Rep. 2011;8:54–61.
   PubMedGoogle Scholar
• Kumari G, Singh RK. Highly active antiretroviral therapy for treatment of HIV/AIDS patients: current status and future prospects and the Indian scenario. HIV AIDS Rev. 2012;11:5–14.
   Google Scholar
• Arts EJ, Hazuda DJ. HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect Med. 2012; 2:a007161.
   PubMed Web of Science ®Google Scholar
• Maenza J, Flexner C. Combination antiretroviral therapy for HIV infection. Am Fam Physician. 1998;57:2789–2798.
   PubMed Web of Science ®Google Scholar
• Taiwo B, Hicks C, Eron J. Unmet therapeutic needs in the new era of combination antiretroviral therapy for HIV-1. J Antimicrob Chemother. 2010;65:1100–1107.
   PubMed Web of Science ®Google Scholar
• Lenjisa JL, Woldu MA, Satessa GD. New hope for eradication of HIV from the body: the role of polymeric nanomedicines in HIV/AIDS pharmacotherapy. J Nanobiotechnol. 2014;12:9.
   PubMed Web of Science ®Google Scholar
• Cory TJ, Schacker TW, Stevenson M, et al. Overcoming pharmacologic sanctuaries. Curr Opin HIV AIDS. 2013;8:190–195.
   PubMed Web of Science ®Google Scholar
• Abbott NJ, Patabendige AAK, Dolman DEM, et al. Structure and function of the blood-brain barrier. Neurobiol Dis. 2010;37:13–25.
   PubMed Web of Science ®Google Scholar
• Abbott NJ. Blood-brain barrier structure and function and the challenges for CNS drug delivery. J Inherit Metab Dis. 2013;36:437–449.
   PubMed Web of Science ®Google Scholar
• Sagar V, Pilakka-Kanthikeel S, Pottathil R, et al. Towards nanomedicines for neuroAIDS. Rev Med Virol. 2014;24:103–124.
   PubMed Web of Science ®Google Scholar
• Tajes M, Ramos-Fernández E, Weng-Jiang X, et al. The blood-brain barrier: structure, function and therapeutic approaches to cross it. Mol Membr Biol. 2014;31:152–167.
   PubMed Web of Science ®Google Scholar
• Das MK, Chakraborty T. Progress in brain delivery of anti-HIV drugs. J Appl Pharm Sci. 2015;5:154–164.
   Google Scholar
• Grabrucker AM, Chhabra R, Belletti D, et al. Nanoparticles as blood-brain barrier permeable cns targeted drug delivery systems. Top Med Chem. 2014;10:71–90.
   Google Scholar
• Nowacek AGH. NanoART, neuroAIDS and CNS drug delivery. Nanomedicine (Lond). 2010;4:557–574.
   Web of Science ®Google Scholar
• Golden PL, Pollack GM. Blood-brain barrier efflux transport. J Pharm Sci. 2003;92:1739–1753.
   PubMed Web of Science ®Google Scholar
• Kusuhara H, Sugiyama Y. Efflux transport systems for drugs at the blood – brain barrier and blood – cerebrospinal fluid barrier (Part 1). Drug Discov Today. 2001;6:1–4.
   PubMedGoogle Scholar
• Lo W, Potschka H. Blood-Brain Barrier Active Efflux Transporters: ATP-Binding Cassette Gene family. NeuroRx J. Neurorx.2005;2:86–98.
   PubMedGoogle Scholar
• Edwards JE, Brouwer KR, McNamara PJ. GF120918, a P-glycoprotein modulator, increases the concentration of unbound amprenavir in the central nervous system in rats. Antimicrob Agents Chemother. 2002;46:2284–2286.
   PubMed Web of Science ®Google Scholar
• Washington CB, Wiltshire HR, Man M, et al. The disposition of saquinavir in normal and P-glycoprotein deficient mice, rats, and in cultured cells. Drug Metab Dispos. 2000;28:1058–1062.
   PubMed Web of Science ®Google Scholar
• Holly J, Perks C. The role of insulin-like growth factor binding proteins. Neuroendocrinology. 2006;83:154–160.
   PubMed Web of Science ®Google Scholar
• Pardridge WM, Eisenberg J, Yang J. Human blood-brain barrier insulin receptor. J Neurochem. 1985;44:1771–1778.
   PubMed Web of Science ®Google Scholar
• Pardridge WM, Eisenberg J, Yang J. Human blood-brain barrier transferrin receptor. Metab Clin Exp. 1987;36:892–895.
   PubMed Web of Science ®Google Scholar
• Duffy KR, Pardridge WM. Blood-brain barrier transcytosis of insulin in developing rabbits. Brain Res. 1987;420:32–38.
   PubMed Web of Science ®Google Scholar
• Ulbrich K, Knobloch T, Kreuter J. Targeting the insulin receptor: nanoparticles for drug delivery across the blood-brain barrier (BBB). J Drug Target. 2011;19:125–132.
   PubMed Web of Science ®Google Scholar
• Dieu LH, Wu D, Palivan CG, et al. Polymersomes conjugated to 83-14 monoclonal antibodies: in vitro targeting of brain capillary endothelial cells. Eur J Pharm Biopharm. 2014;6:2146–2152.
   Google Scholar
• Shilo M, Motiei M, Hana P, et al. Transport of nanoparticles through the blood-brain barrier for imaging and therapeutic applications. Nanoscale. 2014;6:2146–2152.
   PubMed Web of Science ®Google Scholar
• Pardridge WM, Kang YS, Buciak JL, et al. Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood–brain barrier in vivo in the primate. Pharm Res. 1995;12:807–816.
   PubMed Web of Science ®Google Scholar
• Wu D, Yang J, Pardridge WM. Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor. J Clin Invest. 1997;100:1804–1812.
   PubMed Web of Science ®Google Scholar
• Boado RJ, Zhang Y, Zhang Y, et al. Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier. Biotechnol Bioeng. 2007;96:381–391.
   PubMed Web of Science ®Google Scholar
• Duffy KR, Pardridge WM, Rosenfeld RG. Human blood-brain barrier insulin-like growth factor receptor. Metab Clin Exp. 1988;37:136–140.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab. 2012;32:1959–1972.
   PubMed Web of Science ®Google Scholar
• Zong T, Mei L, Gao H, et al. Synergistic dual-ligand doxorubicin liposomes improve targeting and therapeutic efficacy of brain glioma in animals. Mol Pharm. 2014;11:2346–2357.
   PubMed Web of Science ®Google Scholar
• Ulbrich K, Hekmatara T, Herbert E, et al. Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur J Pharm Biopharm. 2009;71:251–256.
   PubMed Web of Science ®Google Scholar
• Sonali AP, Singh RP, Rajesh CV, et al. Transferrin receptor-targeted vitamin E TPGS micelles for brain cancer therapy: preparation, characterization and brain distribution in rats. Drug Deliv. 2015;7544:1–11.
   Google Scholar
• Loureiro JA, Gomes B, Fricker G, et al. Cellular uptake of PLGA nanoparticles targeted with anti-amyloid and anti-transferrin receptor antibodies for Alzheimer’s disease treatment. Colloids Surf B Biointerfaces. 2016;145:8–13.
   PubMed Web of Science ®Google Scholar
• Wei L, Guo XY, Yang T, et al. Brain tumor-targeted therapy by systemic delivery of siRNA with Transferrin receptor-mediated core-shell nanoparticles. Int J Pharm. 2016;510:394–405.
   PubMedGoogle Scholar
• De Luca MA, Lai F, Corrias F, et al. Lactoferrin- and antitransferrin-modified liposomes for brain targeting of the NK3 receptor agonist senktide: preparation and in vivo evaluation. Int J Pharm. 2015;479:129–137.
   PubMed Web of Science ®Google Scholar
• Fillebeen C, Descamps L, Dehouck M, et al. Receptor-mediated transcytosis of lactoferrin through the blood-brain barrier. J Biol Chem. 1999;274:7011–7017.
   PubMed Web of Science ®Google Scholar
• Dehouck B, Fenart L, Dehouck MP, et al. A new function for the LDL receptor: transcytosis of LDL across the blood-brain barrier. J Cell Biol. 1997;138:877–889.
   PubMed Web of Science ®Google Scholar
• Demeule M, Regina A, Che C, et al. Identification and design of peptides as a new drug delivery system for the brain. J Pharmacol Exp Ther. 2007;324:1064–1072.
   PubMed Web of Science ®Google Scholar
• Demeule M, Currie JC, Bertrand Y, et al. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector Angiopep-2. J Neurochem. 2008;106:1534–1544.
   PubMed Web of Science ®Google Scholar
• Lu F, Pang Z, Zhao J, et al. Angiopep-2-conjugated poly(ethylene glycol)-co-poly(ε-caprolactone) polymersomes for dual-targeting drug delivery to glioma in rats. Int J Nanomedicine. 2017;12:2117–2127.
   PubMed Web of Science ®Google Scholar
• Demeule M, Che C, Lavalle I. Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br J Pharmacol. 2008;155:185–197.
   PubMed Web of Science ®Google Scholar
• Ćurić A, Möschwitzer JP, Fricker G. Development and characterization of novel highly-loaded itraconazole poly(butyl cyanoacrylate) polymeric nanoparticles. Eur J Pharm Biopharm. 2017;114:175–185.
   PubMed Web of Science ®Google Scholar
• Neves AR, Queiroz JF, Reis S. Brain-targeted delivery of resveratrol using solid lipid nanoparticles functionalized with apolipoprotein E. J Nanobiotechnol. 2016;14:27.
   PubMed Web of Science ®Google Scholar
• Demeule M, Poirier J, Jodoin J, et al. High transcytosis of melanotransferrin (P97) across the blood-brain barrier. J Neurochem. 2002;83:924–933.
   PubMed Web of Science ®Google Scholar
• Karkan D, Pfeifer C, Vitalis TZ, et al. A unique carrier for delivery of therapeutic compounds beyond the blood-brain barrier. PLoS One. 2008; 3:e2469
   PubMed Web of Science ®Google Scholar
• Gaillard PJ, Brink A, de Boer AG. Diphtheria toxin receptor-targeted brain drug delivery. Int Congr Ser. 2005;1277:185–198.
   Google Scholar
• G, Giannini RR, GR. The amino-acid sequence of two non-toxic mutants of diphtheria toxin: CRM45 and CRM197. Nucleic Acids Res. 1984;12:4063–4069.
   PubMed Web of Science ®Google Scholar
• Buzzi S, Rubboli D, Buzzi G, et al. CRM197 (nontoxic diphtheria toxin): effects on advanced cancer patients. Cancer Immunol Immunother. 2004;53:1041–1048.
   PubMed Web of Science ®Google Scholar
• Chen Y, Liu L. Modern methods for delivery of drugs across the blood-brain barrier. Adv Drug Deliv Rev. 2012;64:640–665.
   PubMed Web of Science ®Google Scholar
• Patel MM, Goyal BR, Bhadada SV, et al. Getting into the brain: approaches to enhance brain drug delivery. CNS Drugs. 2009; 23:35–58.
   PubMed Web of Science ®Google Scholar
• Nutt JG, Woodward WR, Hammerstad JP, et al. The “on-off” phenomenon in Parkinson’s disease. Relation to levodopa absorption and transport. N Engl J Med. 1984;310:483–488.
   PubMed Web of Science ®Google Scholar
• Li L, Di X, Zhang S, et al. Large amino acid transporter 1 mediated glutamate modified docetaxel-loaded liposomes for glioma targeting. Colloids Surf B Biointerfaces. 2016;141:260–267.
   PubMed Web of Science ®Google Scholar
• Peura L, Malmioja K, Huttunen K, et al. Design, synthesis and brain uptake of lat1-targeted amino acid prodrugs of dopamine. Pharm Res. 2013;30:2523–2537.
   PubMed Web of Science ®Google Scholar
• Gynther M, Laine K, Ropponen J, et al. Large neutral amino acid transporter enables brain drug delivery via prodrugs. J Med Chem. 2008;51:932–936.
   PubMed Web of Science ®Google Scholar
• Stenehjem DD, Hartz AMS, Bauer B, et al. Novel and emerging strategies in drug delivery for overcoming the blood-brain barrier. Future Med Chem. 2009;1:1623–1641.
   PubMed Web of Science ®Google Scholar
• Bragagni M, Mennini N, Furlanetto S, et al. Development and characterization of functionalized niosomes for brain targeting of dynorphin-B. Eur J Pharm Biopharm. 2014;87:73–79.
   PubMed Web of Science ®Google Scholar
• Jiang X, Xin H, Ren Q, et al. Nanoparticles of 2-deoxy-d-glucose functionalized poly(ethylene glycol)-co-poly(trimethylene carbonate) for dual-targeted drug delivery in glioma treatment. Biomaterials. 2014;35:518–529.
   PubMed Web of Science ®Google Scholar
• Halmos T, Santarromana M, Antonakis KSD. Synthesis of glucose-chlorambucil derivatives and their recognition by the human GLUT1 glucose transporter. Eur J Pharmacol. 1996;318:477–484.
   PubMed Web of Science ®Google Scholar
• Rorer R, Chimie L, De, Biologique, O. Synthesis of O-methylsulfonyl derivatives of D-glucose as potential alkylating agents for targeted drug delivery to the brain. Evaluation of their interaction with the human erythrocyte GLUT1 hexose transporter. Carbohydr Res. 1997;299:15–21.
   PubMed Web of Science ®Google Scholar
• Ying X, Wen H, Lu WL, et al. Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. J Control Release. 2010;141:183–192.
   PubMed Web of Science ®Google Scholar
• Du D, Chang N, Sun S, et al. The role of glucose transporters in the distribution of p-aminophenyl-α-d-mannopyranoside modified liposomes within mice brain. J Control Release. 2014;182:99–110.
   PubMed Web of Science ®Google Scholar
• Enerson BE, Drewes LR. Molecular features, regulation, and function of monocarboxylate transporters: Implications for drug delivery. J Pharm Sci. 2003;92:1531–1544.
   PubMed Web of Science ®Google Scholar
• Tsuji A, Saheki A, Tamai I, et al. Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier. J Pharmacol Exp Ther. 1993;267:1085–1090.
   PubMed Web of Science ®Google Scholar
• Sierra S, Ramos MC, Molina P, et al. Statins as neuroprotectants: a comparative in vitro study of lipophilicity, blood-brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death. J Alzheimer’s Dis. 2011;23:307–318.
   PubMed Web of Science ®Google Scholar
• Lee N-Y, Kang Y-S. In vivo and in vitro evidence for brain uptake of 4-phenylbutyrate by the monocarboxylate transporter 1 (MCT1). Pharm Res. 2016;1:1711–1722.
   Google Scholar
• Lanius RA, Shaw CA, Wagey R, et al. Characterization, distribution, and protein kinase C-mediated regulation of [35S]glutathione binding sites in mouse and human spinal cord. J Neurochem. 1994;63:155–160.
   PubMed Web of Science ®Google Scholar
• Kannan R, Chakrabarti R, Tang D, et al. GSH transport in human cerebrovascular endothelial cells and human astrocytes: evidence for luminal localization of Na+-dependent GSH transport in HCEC. Brain Res. 2000;852:374–382.
   PubMed Web of Science ®Google Scholar
• Gaillard PJ, Appeldoorn CCM, Dorland R, et al. Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101). PLoS One. 2014;9:e82331.
   PubMed Web of Science ®Google Scholar
• Rip J, Chen L, Hartman R, et al. Glutathione PEGylated liposomes: pharmacokinetics and delivery of cargo across the blood-brain barrier in rats. J Drug Target. 2014;22:460–467.
   PubMed Web of Science ®Google Scholar
• Gaillard PJ, Appeldoorn CCM, Rip J, et al. Enhanced brain delivery of liposomal methylprednisolone improved therapeutic efficacy in a model of neuroinflammation. J Control Release. 2012;164:364–369.
   PubMed Web of Science ®Google Scholar
• Patel PJ, Acharya SR. Design and development of glutathione conjugated poly (d, l) lactide nanocarriers for delivery of hydrophilic fluorescent marker across blood brain barrier. Curr Nanosci. 2012;8:847–857.
   Web of Science ®Google Scholar
• Acharya SR, Reddy PRV. Brain targeted delivery of paclitaxel using endogenous ligand. Asian J Pharm Sci. 2016;11:427–438.
   Web of Science ®Google Scholar
• Geldenhuys W, Mbimba T, Bui T, et al. Brain-targeted delivery of paclitaxel using glutathione-coated nanoparticles for brain cancers. J Drug Target. 2011;19:837–845.
   PubMed Web of Science ®Google Scholar
• Raval N, Mistry T, Acharya N, et al. Development of glutathione-conjugated asiatic acid-loaded bovine serum albumin nanoparticles for brain-targeted drug delivery. J Pharm Pharmacol. 2015;67:1503–1511.
   PubMed Web of Science ®Google Scholar
• Allen DD, Lockman PR. The blood-brain barrier choline transporter as a brain drug delivery vector. Life Sci. 2003;73:1609–1615.
   PubMed Web of Science ®Google Scholar
• Geldenhuys WJ, Allen DD. The blood-brain barrier choline transporter. Cent Nerv Syst Agents Med Chem. 2012;12:95–99.
   PubMedGoogle Scholar
• Li J, Zhou L, Ye D, et al. Choline-derivate-modified nanoparticles for brain-targeting gene delivery. Adv Mater Weinheim. 2011;23:4516–4520.
   PubMed Web of Science ®Google Scholar
• Gao H. Progress and perspectives on targeting nanoparticles for brain drug delivery. Acta Pharm Sin B. 2016;6:268–286.
   PubMed Web of Science ®Google Scholar
• Lu W, Sun Q, Wan J, et al. Cationic albumin-conjugated pegylated nanoparticles allow gene delivery into brain tumors via intravenous administration. Cancer Res. 2006;66:11878–11887.
   PubMed Web of Science ®Google Scholar
• Guo L, Ren J, Jiang X. Perspectives on brain-targeting drug delivery systems. Curr Pharm Biotechnol. 2012;13:2310–2318.
   PubMed Web of Science ®Google Scholar
• Jain A, Jain A, Garg NK, et al. Surface engineered polymeric nanocarriers mediate the delivery of transferrin-methotrexate conjugates for an improved understanding of brain cancer. Acta Biomater. 2015;24:140–151.
   PubMed Web of Science ®Google Scholar
• Díaz-perlas C, Sanchez–Navarro M, Oller-Salvia B, et al. Phage display as a tool to discover blood – brain barrier (BBB) – shuttle peptides: panning against a human BBB cellular model. Pept Sci. 2017;108:e22928.
   Google Scholar
• Bakhshinejad B, Karimi M, Khalaj-kondori M. Phage display: development of nanocarriers for targeted drug delivery to the brain. Neural Regen Res. 2015;10:862–865.
   PubMed Web of Science ®Google Scholar
• Nemudraya AA, Richter VA, Kuligina EV. Phage peptide libraries as a source of targeted ligands. Acta Naturae. 2016;8:48–57.
   PubMed Web of Science ®Google Scholar
• Benjamí Oller-Salvia M, Sánchez-Navarro E, Giraltab MT. Blood–brain barrier shuttle peptides: an emerging paradigm for brain delivery. Chem Soc Rev. 2016;45:4690–4707.
   PubMed Web of Science ®Google Scholar
• Zhang C, Liu Q, Shao X, et al. Phage-displayed peptide-conjugated biodegradable nanoparticles enhanced brain drug delivery. Mater Lett. 2016;167:213–217.
   Web of Science ®Google Scholar
• Zhao J, Zhang B, Shen S, et al. CREKA peptide-conjugated dendrimer nanoparticles for glioblastoma multiforme delivery. J Colloid Interface Sci. 2015;450:396–403.
   PubMed Web of Science ®Google Scholar
• Li J, Feng L, Fan L, et al. Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides. Biomaterials. 2011;32:4943–4950.
   PubMed Web of Science ®Google Scholar
• Qian Y, Zha Y, Feng B, et al. PEGylated poly(2-(dimethylamino) ethyl methacrylate)/DNA polyplex micelles decorated with phage-displayed TGN peptide for brain-targeted gene deliver. Biomaterials. 2013;34:2117–2129.
   PubMed Web of Science ®Google Scholar
• Shi W, Cui X, Shi J, et al. Overcoming the blood–brain barrier for gliomatargeted therapy based on an interleukin-6 receptor-mediated micelle system. RSC Adv. 2017;7:27162–27169.
   Web of Science ®Google Scholar
• Cho J, Kim A, Kim S, et al. Development of a novel imaging agent using peptide-coated gold nanoparticles toward brain glioma stem cell marker CD133. Acta Biomater. 2017;47:182–192.
   PubMed Web of Science ®Google Scholar
• Roy U, Barber P, Sarmento B, et al. The potential of HIV-1 nanotherapeutics: from in vitro studies to clinical trials. Nanomedicine (Lond). 2015;10:3597–3609.
   PubMed Web of Science ®Google Scholar
• Govender T, Ojewole E, Naidoo P, et al. Polymeric nanoparticles for enhancing antiretroviral drug therapy. Drug Deliv. 2008;15:493–501.
   PubMed Web of Science ®Google Scholar
• Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces. 2010;75:1–18.
   PubMed Web of Science ®Google Scholar
• Wong HL, Chattopadhyay N, Wu XY, et al. Nanotechnology applications for improved delivery of antiretroviral drugs to the brain. Adv Drug Deliv Rev. 2010;62:503–517.
   PubMed Web of Science ®Google Scholar
• Rao KS, Reddy MK, Horning JL, et al. TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs. Biomaterials. 2008;29:4429–4438.
   PubMed Web of Science ®Google Scholar
• Destache CJ, Belgum T, Goede M, et al. Antiretroviral release from poly(DL-lactide-co-glycolide) nanoparticles in mice. J Antimicrob Chemother. 2010;65:2183–2187.
   PubMed Web of Science ®Google Scholar
• Kuo YC, Chen HH. Effect of nanoparticulate polybutylcyanoacrylate and methylmethacrylate-sulfopropylmethacrylate on the permeability of zidovudine and lamivudine across the in vitro blood-brain barrier. Int J Pharm. 2006;327:160–169.
   PubMed Web of Science ®Google Scholar
• Kuo YC, Chung CY. Transcytosis of CRM197-grafted polybutylcyanoacrylate nanoparticles for delivering zidovudine across human brain-microvascular endothelial cells. Colloids Surf B Biointerfaces. 2012;91:242–249.
   PubMed Web of Science ®Google Scholar
• Kuo YC, Su FL. Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate-sulfopropylmethacrylate, and solid lipid nanoparticles. Int J Pharm. 2007;340:143–152.
   PubMed Web of Science ®Google Scholar
• Kuo YC, Lee CL. Methylmethacrylate-sulfopropylmethacrylate nanoparticles with surface RMP-7 for targeting delivery of antiretroviral drugs across the blood-brain barrier. Colloids Surf B Biointerfaces. 2012;90:75–82.
   PubMed Web of Science ®Google Scholar
• Spitzenberger TJ, Heilman D, Diekmann C, et al. Novel delivery system enhances efficacy of antiretroviral therapy in animal model for HIV-1 encephalitis. J Cereb Blood Flow Metab. 2007;27:1033–1042.
   PubMed Web of Science ®Google Scholar
• Shaik N, Pan G, Elmquist WF. Interactions of pluronic block copolymers on P-gp efflux activity: experience with HIV-1 protease inhibitors. J Pharm Sci. 2008;97:5421–5433.
   PubMed Web of Science ®Google Scholar
• Gu J, Al-Bayati K, Ho EA. Development of antibody-modified chitosan nanoparticles for the targeted delivery of siRNA across the blood-brain barrier as a strategy for inhibiting HIV replication in astrocytes. Drug Deliv Transl Res. 2017;7:497–506.
   PubMed Web of Science ®Google Scholar
• Al-Ghananeem AM, Saeed H, Florence R, et al. Intranasal drug delivery of didanosine-loaded chitosan nanoparticles for brain targeting; an attractive route against infections caused by AIDS viruses. J Drug Target. 2010;18:381–388.
   PubMed Web of Science ®Google Scholar
• Belgamwar A, Khan S, Yeole P. Intranasal chitosan-g-HPβCD nanoparticles of efavirenz for the CNS targeting. Artif Cells Nanomed Biotechnol. 2017;19:1–13.
   Google Scholar
• Mishra V, Mahor S, Rawat A, et al. Targeted brain delivery of AZT via transferrin anchored pegylated albumin nanoparticles. J Drug Target. 2006;14:45–53.
   PubMed Web of Science ®Google Scholar
• Kaur A, Jain S, Tiwary AK. Mannan-coated gelatin nanoparticles for sustained and targeted delivery of didanosine: in vitro and in vivo evaluation. Acta Pharm. 2008;58:61–74.
   PubMed Web of Science ®Google Scholar
• Almeida AJ, Souto E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Deliv Rev. 2007;59:478–490.
   PubMed Web of Science ®Google Scholar
• Gupta S, Kesarla R, Chotai N, et al. Systematic approach for the formulation and optimization of solid lipid nanoparticles of efavirenz by high pressure homogenization using design of experiments for brain targeting and enhanced bioavailability. Biomed Res Int. 2017;2017:5984014.
   PubMed Web of Science ®Google Scholar
• Vyas A, Jain A, Hurkat P, et al. Targeting of AIDS related encephalopathy using phenylalanine anchored lipidic nanocarrier. Colloids Surf B Biointerfaces. 2015;131:155–161.
   PubMed Web of Science ®Google Scholar
• Chattopadhyay N, Zastre J, Wong HL, et al. Solid lipid nanoparticles enhance the delivery of the HIV protease inhibitor, atazanavir, by a human brain endothelial cell line. Pharm Res. 2008;25:2262–2271.
   PubMed Web of Science ®Google Scholar
• Kuo YC, Kuo CY. Electromagnetic interference in the permeability of saquinavir across the blood-brain barrier using nanoparticulate carriers. Int J Pharm. 2008;351:271–281.
   PubMed Web of Science ®Google Scholar
• Ojewole E, Mackraj I, Naidoo P, et al. Exploring the use of novel drug delivery systems for antiretroviral drugs. Eur J Pharm Biopharm. 2008;70:697–710.
   PubMed Web of Science ®Google Scholar
• Ding H, Sagar V, Agudelo M, et al. Enhanced blood-brain barrier transmigration using a novel Transferrin-embedded fluorescent magnetoliposome nanoformulation. Nanotechnology. 2015;25:055101.
   Web of Science ®Google Scholar
• Kim S, Scheerer S, Geyer MA, et al. Direct cerebrospinal fluid delivery of an antiretroviral agent using multivesicular liposomes. J Infect Dis. 1990;162:750–752.
   PubMed Web of Science ®Google Scholar
• Jin SX, Bi DZ, Wang J, et al. Pharmacokinetics and tissue distribution of zidovudine in rats following intravenous administration of zidovudine myristate loaded liposomes. Pharmazie. 2005;60:840–843.
   PubMed Web of Science ®Google Scholar
• Batrakova EV, Li S, Alakhov VY, et al. Optimal structure requirements for pluronic block copolymers in modifying P-glycoprotein drug efflux transporter activity in bovine brain microvessel endothelial cells. J Pharmacol Exp Ther. 2003;304:845–854.
   PubMed Web of Science ®Google Scholar
• Shegokar R, Singh KK. Surface modified nevirapine nanosuspensions for viral reservoir targeting: in vitro and in vivo evaluation. Int J Pharm. 2011;421:341–352.
   PubMed Web of Science ®Google Scholar
• Shegokar R, Jansch M, Singh KK, et al. In vitro protein adsorption studies on nevirapine nanosuspensions for HIV/AIDS chemotherapy. Nanomed Nanotechnol Biol Med. 2011;7:333–340.
   PubMed Web of Science ®Google Scholar
• Dash PK, Gendelman HE, Roy U, et al. Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice. AIDS. 2012;26:2135–2144.
   PubMed Web of Science ®Google Scholar
• Mahajan SD, Roy I, Xu G, et al. Enhancing the delivery of anti retroviral drug “Saquinavir” across the blood brain barrier using nanoparticles. Curr Hiv Res. 2010;8:396–404.
   PubMed Web of Science ®Google Scholar
• Fiandra L, Colombo M, Mazzucchelli S, et al. Nanoformulation of antiretroviral drugs enhances their penetration across the blood brain barrier in mice. Nanomed Nanotechnol Biol Med. 2015;11:1387–1397.
   PubMed Web of Science ®Google Scholar
• Mahajan SD, Law WC, Aalinkeel R, et al. Nanoparticle-mediated targeted delivery of antiretrovirals to the brain. Methods Enzymol. 2012; 509:41–60.
   PubMed Web of Science ®Google Scholar
• Kandadi P, Syed MA, Goparaboina S, et al. Brain specific delivery of pegylated indinavir submicron lipid emulsions. Eur J Pharm Sci. 2011;42:423–432.
   PubMed Web of Science ®Google Scholar
• Anil B, Jindal Sagar S, Bachhav Padma VD. In situ hybrid nano drug delivery system (IHN-DDS) of antiretroviral drug for simultaneous targeting to multiple viral reservoirs: an in vivo proof of concept. Int J Pharm. 2017;521:196–203.
   PubMedGoogle Scholar
• Rodriguez M, Kaushik A, Lapierre J, et al. Electro-magnetic nano-particle bound Beclin1 siRNA crosses the blood – brain barrier to attenuate the inflammatory effects of HIV-1 infection in vitro. J Neuroimmune Pharmacol. 2017;12:120–132.
   PubMed Web of Science ®Google Scholar
• Rodriguez M, La J, Raj C, et al. Intranasal drug delivery of small interfering RNA targeting Beclin1 encapsulated with polyethylenimine (PEI) in mouse brain to achieve HIV attenuation. Sci Rep. 2017;7:1–10.
   PubMed Web of Science ®Google Scholar
• Wang Q, Zhang Y, Qian S, et al. Pharmacokinetics and brain uptake of HIV-1 replication inhibitor DB213 in Sprague–Dawley rats. J Pharm Biomed Anal. 2016;125:41–47.
   PubMed Web of Science ®Google Scholar